Morgan Stanley lowered the firm’s price target on Alnylam (ALNY) to $268 from $284 and keeps an Equal Weight rating on the shares. The firm is slightly below consensus on Q1 TTR franchise sales, but expects a focus on early launch dynamics for Amvuttra in ATTR-CM, the analyst tells investors in a preview heading into earnings for commercial small-to-mid cap biotechnology companies the analyst covers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharma’s Strong Market Position and Growth Potential Justify Buy Rating
- Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy
- Hold Rating on Alnylam Pharma’s Qfitlia Amid FDA Approval and Market Challenges
- Cautious Outlook for Alnylam Pharma Amid Promising Developments and Market Challenges
- Alnylam Pharma’s Strategic Positioning and Financial Prospects Drive Buy Rating Amid AMVUTTRA Approval